Victory Capital Management Inc. Has $551.27 Million Position in Johnson & Johnson (NYSE:JNJ)

Victory Capital Management Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 9.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,063,174 shares of the company’s stock after acquiring an additional 251,692 shares during the quarter. Johnson & Johnson comprises 0.6% of Victory Capital Management Inc.’s portfolio, making the stock its 11th biggest holding. Victory Capital Management Inc. owned 0.12% of Johnson & Johnson worth $551,268,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Magnolia Capital Management Ltd. increased its holdings in shares of Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after acquiring an additional 55 shares during the last quarter. Howard Financial Services LTD. increased its holdings in shares of Johnson & Johnson by 2.1% during the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares during the last quarter. American Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 2.1% during the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares during the last quarter. Capital Investment Counsel Inc grew its holdings in Johnson & Johnson by 0.8% in the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after buying an additional 59 shares in the last quarter. Finally, Kwmg LLC grew its holdings in Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $171.79 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a market cap of $451.67 billion, a P/E ratio of 25.01, a P/E/G ratio of 3.29 and a beta of 0.59. The business has a fifty day simple moving average of $175.41 and a 200 day simple moving average of $174.52.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the prior year, the company earned $2.48 EPS. Johnson & Johnson’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. UBS Group decreased their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Raymond James upped their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Finally, Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Insider Buying and Selling

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.